1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Sue was shocked to find her pain, weakness and broken bones were the result of cancer that had spread from her #kidney . The complexity of her situation led her to Johns Hopkins Medicine where she received multi-d care from nirm, Dr. Yasser Ged & more.
hopkinsmedicine.org/health/conditi…

Thanks GU Oncology Now for highlighting our work published in Urologic Oncology led by The Johns Hopkins Brady Urological Institute Johns Hopkins Medicine Society of Urologic Oncology fellow Michael E. Rezaee, MD, MPH! #kidneycancer

Thanks Urologic Oncology for highlighting our work from The Johns Hopkins Brady Urological Institute Johns Hopkins Medicine led by Society of Urologic Oncology fellow Michael E. Rezaee, MD, MPH

In a session at #IKCSNA23 , Dr. Yasser Ged discussed emerging treatment approaches for patients with metastatic translocation renal cell carcinoma. #urology #urologist #kcsm Kidney Cancer Yasserged Johns Hopkins Kimmel Cancer Center The Johns Hopkins Brady Urological Institute

Read more: urologytimes.com/view/researche…

Benjamin L Maughan with discussion of SWOG Cancer Research Network #PAPMET 2 trial, based on #PAPMET completion! #IKCSNA23 Kidney Cancer KCCure

Happy to share our findings at #IKCSNA23 ! In our single-institution retrospective cohort, no evidence of superiority of either IO/IO or TKI/IO in #kidneycancer 1L tx with regard to PFS2, including in groups w/ sarcomatoid features, BAP1 mutation, or deep RECIST response.

Thank you Yasserged for highlighting our work and Shuchi Gulati MD for the shout-out!
Sorry to be missing #IKCSNA23

Srinivas Viswanathan Toni Choueiri, MD Eli Van Allen

Thank you Urology Times for the recent series of interviews highlighting our work on socioeconomic and racial disparities in #kidneycancer Lots of work to do to close the gap! Urologic Oncology The Johns Hopkins Brady Urological Institute Johns Hopkins Medicine Ridwan Alam Roy Elias

Great work By dery alamsyah online now 'Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma' nirm
sciencedirect.com/science/articl…

Online Now: Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy dlvr.it/StyX0V

Belzutifan (HIF2a transcription factor) has a ‘clinically meaningful’ ⬆️ in PFS and response rates vs. everolimus in heavily pretreated advanced clear cell RCC patients. A ‘non significant trend towards OS’ was seen at interim analysis. Final OS awaited businesswire.com/news/home/2023…

#ezrabaraban needs a Twitter handle, or I need to know what it is! Fantastic work from him looking at #PSMA in a subtype of renal cell carcinomas. pubmed.ncbi.nlm.nih.gov/37471632/ Mohamad Allaf Michael Gorin, M.D. Mark C. Markowski nirm

Artificial intelligence for multimodal data integration in oncology dlvr.it/Sb627k

Just In Kidney Cancer: Excellent systematic review on the current status of urine-based markers for #KidneyCancer by Barbara Köditz et al👉Need for the development of urinary biomarkers for detection, progression & prognostication for mRCC 👉bit.ly/3CPoMfT KidneyCAN

JUST IN: #KCRS22 slides and videos are in ! KidneyCAN

Hans Hammers Bryan Lewis Sumanta K. Pal, MD, FASCO Rana McKay Tian Zhang, MD, MHS Brian Rini, MD Fabio Schutz Brian Shuch, MD Tom Powles Laurence Albiges Signoretti Lab Bradley McGregor Praful Ravi Chris Labaki Renee Maria Saliby David Braun Neeraj Agarwal, MD, FASCO

Our paper on FGFR3 alterations and sensitivity to platinum-based chemo is out in European Urology ! Thanks to Min Yuen Teo 張鳴元 Jonathan Rosenberg MD Gopa Iyer and all the @sloan_kettering GU service!

New #JITC article: DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy ow.ly/DdJq50Aeq4D